2,4-thiazolidinedione has been researched along with Anasarca in 17 studies
thiazolidine-2,4-dione: structure in first source
1,3-thiazolidine-2,4-dione : A thiazolidenedione carrying oxo substituents at positions 2 and 4.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Genetic variation at the NFATC2 locus contributes to edema among individuals who receive rosiglitazone." | 7.76 | Variation at the NFATC2 locus increases the risk of thiazolidinedione-induced edema in the Diabetes REduction Assessment with ramipril and rosiglitazone Medication (DREAM) study. ( Anand, S; Bailey, SD; Diaz, R; Do, R; Engert, JC; Gerstein, HC; Keavney, B; Mohan, V; Montpetit, A; Xie, C; Yusuf, S, 2010) |
| " Preliminary works accomplished at our laboratory with 2,4-thiazolidinedione isosters demonstrated inhibitory activity on edema formation for N-tryptophyl-5-(3,5-di-tert-butyl-4-hydroxybenzylidene)-2,4-thiazolidinedione (GS28) and N-tryptophyl-5-(3,5-di-tert-butyl-4-hydroxybenzylidene) rhodanine (GS26)." | 7.72 | Antiedematogenic activity of two thiazolidine derivatives: N-tryptophyl-5-(3,5-di-tert-butyl-4-hydroxybenzylidene) rhodanine (GS26) and N-tryptophyl-5-(3,5-di-tert-butyl-4-hydroxybenzylidene)-2,4-thiazolidinedione (GS28). ( da Silva Góes, AJ; de Lima, WT; de Souza Maia, MB; Rodrigues e Silva, AA, 2003) |
| "Genetic variation at the NFATC2 locus contributes to edema among individuals who receive rosiglitazone." | 3.76 | Variation at the NFATC2 locus increases the risk of thiazolidinedione-induced edema in the Diabetes REduction Assessment with ramipril and rosiglitazone Medication (DREAM) study. ( Anand, S; Bailey, SD; Diaz, R; Do, R; Engert, JC; Gerstein, HC; Keavney, B; Mohan, V; Montpetit, A; Xie, C; Yusuf, S, 2010) |
| " Preliminary works accomplished at our laboratory with 2,4-thiazolidinedione isosters demonstrated inhibitory activity on edema formation for N-tryptophyl-5-(3,5-di-tert-butyl-4-hydroxybenzylidene)-2,4-thiazolidinedione (GS28) and N-tryptophyl-5-(3,5-di-tert-butyl-4-hydroxybenzylidene) rhodanine (GS26)." | 3.72 | Antiedematogenic activity of two thiazolidine derivatives: N-tryptophyl-5-(3,5-di-tert-butyl-4-hydroxybenzylidene) rhodanine (GS26) and N-tryptophyl-5-(3,5-di-tert-butyl-4-hydroxybenzylidene)-2,4-thiazolidinedione (GS28). ( da Silva Góes, AJ; de Lima, WT; de Souza Maia, MB; Rodrigues e Silva, AA, 2003) |
| "Combination of insulin and rosiglitazone is effective in massively obese patients with Type 2 diabetes, though there is a high incidence of peripheral oedema." | 3.71 | Combination of insulin and thiazolidinedione therapy in massively obese patients with Type 2 diabetes. ( Akarca, C; Barton, DM; Baskar, V; Buch, HN; Kamalakannan, D; Singh, BM, 2002) |
| "The incidence of obesity and type 2 diabetes mellitus (DM2) in the United States has been increasing dramatically over the past 15 years, and is now at epidemic proportions." | 2.42 | Cardiovascular implications of thiazolidinedione therapy. ( King, D; Lamb, RE, 2004) |
| "Edema is an adverse event associated with thiazolidinedione therapy The potential for mild-to-moderate peripheral edema with thiazolidinedione is known, especially in patients who have heart failure or use insulin." | 2.41 | Thiazolidinedione-induced edema. ( Janney, LM; Niemeyer, NV, 2002) |
| "The first thiazolidinedione derivative drug for diabetes, troglitazone, was found to cause fatal hepatotoxicity, although it was judged as safe during the clinical trial." | 2.41 | [Evaluation of thiazolidinedione derivative drugs for safety]. ( Iwata, M; Kobayashi, M, 2001) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 12 (70.59) | 29.6817 |
| 2010's | 5 (29.41) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ranjan Srivastava, A | 1 |
| Bhatia, R | 1 |
| Chawla, P | 1 |
| Youssef, AM | 1 |
| White, MS | 1 |
| Villanueva, EB | 1 |
| El-Ashmawy, IM | 1 |
| Klegeris, A | 1 |
| Bailey, SD | 1 |
| Xie, C | 2 |
| Do, R | 1 |
| Montpetit, A | 1 |
| Diaz, R | 1 |
| Mohan, V | 1 |
| Keavney, B | 1 |
| Yusuf, S | 1 |
| Gerstein, HC | 1 |
| Engert, JC | 1 |
| Anand, S | 1 |
| Ma, L | 1 |
| Ma, Y | 1 |
| Liu, J | 1 |
| Xiang, M | 1 |
| Ye, X | 1 |
| Zheng, H | 1 |
| Chen, Z | 1 |
| Xu, Q | 1 |
| Chen, T | 1 |
| Chen, J | 1 |
| Yang, J | 1 |
| Qiu, N | 1 |
| Wang, G | 1 |
| Liang, X | 1 |
| Peng, A | 1 |
| Yang, S | 1 |
| Wei, Y | 1 |
| Chen, L | 1 |
| Chang, TJ | 1 |
| Liu, PH | 1 |
| Liang, YC | 1 |
| Chang, YC | 1 |
| Jiang, YD | 1 |
| Li, HY | 1 |
| Lo, MT | 1 |
| Chen, HS | 1 |
| Chuang, LM | 1 |
| Niemeyer, NV | 1 |
| Janney, LM | 1 |
| Tang, WH | 1 |
| Francis, GS | 1 |
| Hoogwerf, BJ | 1 |
| Young, JB | 1 |
| Rodrigues e Silva, AA | 1 |
| da Silva Góes, AJ | 1 |
| de Lima, WT | 1 |
| de Souza Maia, MB | 1 |
| Nesto, RW | 1 |
| Bell, D | 1 |
| Bonow, RO | 1 |
| Fonseca, V | 1 |
| Grundy, SM | 1 |
| Horton, ES | 1 |
| Le Winter, M | 1 |
| Porte, D | 1 |
| Semenkovich, CF | 1 |
| Smith, S | 1 |
| Young, LH | 1 |
| Kahn, R | 1 |
| King, KA | 1 |
| Levi, VE | 1 |
| Lamb, RE | 1 |
| King, D | 1 |
| Wang, F | 1 |
| Vergara, C | 1 |
| Carabino, J | 1 |
| Desilets, A | 1 |
| Vasquez, R | 1 |
| Emoto, M | 1 |
| Fukuda, N | 1 |
| Nakamori, Y | 1 |
| Taguchi, A | 1 |
| Okuya, S | 1 |
| Oka, Y | 1 |
| Tanizawa, Y | 1 |
| Stroup, JS | 1 |
| Ali, AM | 1 |
| Saber, GE | 1 |
| Mahfouz, NM | 1 |
| El-Gendy, MA | 1 |
| Radwan, AA | 1 |
| Hamid, MA | 1 |
| Kobayashi, M | 1 |
| Iwata, M | 1 |
| Buch, HN | 1 |
| Baskar, V | 1 |
| Barton, DM | 1 |
| Kamalakannan, D | 1 |
| Akarca, C | 1 |
| Singh, BM | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| The Influence of Rosiglitazone on the Diuretic Effect of Furosemide and Amiloride. A Double-blind Placebo Controlled Cross Over Study.[NCT00285805] | 13 participants (Actual) | Interventional | 2006-02-28 | Completed | |||
| A Study of PPAR-Gamma Agonist-Rosiglitazone for Determining Cardiac Adverse Effects in Type 2 Diabetic Patients[NCT00300911] | Phase 4 | 45 participants | Interventional | 2005-12-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
4 reviews available for 2,4-thiazolidinedione and Anasarca
| Article | Year |
|---|---|
Thiazolidinedione-induced edema.
Topics: Aged; Edema; Humans; Male; Middle Aged; Thiazoles; Thiazolidinediones | 2002 |
Thiazolidinedione-induced edema.
Topics: Aged; Edema; Humans; Male; Middle Aged; Thiazoles; Thiazolidinediones | 2002 |
Thiazolidinedione-induced edema.
Topics: Aged; Edema; Humans; Male; Middle Aged; Thiazoles; Thiazolidinediones | 2002 |
Thiazolidinedione-induced edema.
Topics: Aged; Edema; Humans; Male; Middle Aged; Thiazoles; Thiazolidinediones | 2002 |
Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association.
Topics: Edema; Heart Failure; Humans; Hypoglycemic Agents; Safety; Thiazolidinediones; Weight Gain | 2004 |
Cardiovascular implications of thiazolidinedione therapy.
Topics: Cardiovascular Diseases; Contraindications; Decision Trees; Diabetes Mellitus, Type 2; Edema; Heart | 2004 |
[Evaluation of thiazolidinedione derivative drugs for safety].
Topics: Animals; Chemical and Drug Induced Liver Injury; Chromans; Clinical Trials as Topic; Edema; Heart Fa | 2001 |
13 other studies available for 2,4-thiazolidinedione and Anasarca
| Article | Year |
|---|---|
Synthesis, biological evaluation and molecular docking studies of novel 3,5-disubstituted 2,4-thiazolidinediones derivatives.
Topics: Animals; Anti-Inflammatory Agents; Antioxidants; Binding Sites; Blood Glucose; Diabetes Mellitus, Ex | 2019 |
Synthesis and biological evaluation of novel pyrazolyl-2,4-thiazolidinediones as anti-inflammatory and neuroprotective agents.
Topics: Animals; Anti-Inflammatory Agents; Cell Line, Tumor; Cyclooxygenase 1; Cyclooxygenase 2; Edema; Gran | 2010 |
Variation at the NFATC2 locus increases the risk of thiazolidinedione-induced edema in the Diabetes REduction Assessment with ramipril and rosiglitazone Medication (DREAM) study.
Topics: Diabetes Mellitus, Type 2; Edema; Female; Humans; Hypoglycemic Agents; Male; NFATC Transcription Fac | 2010 |
Synthesis and biological evaluation of novel 5-benzylidenethiazolidine-2,4-dione derivatives for the treatment of inflammatory diseases.
Topics: Animals; Anti-Inflammatory Agents; Arthritis, Experimental; Benzylidene Compounds; Carrageenan; Cell | 2011 |
Genetic predisposition and nongenetic risk factors of thiazolidinedione-related edema in patients with type 2 diabetes.
Topics: Aged; Alleles; Aquaporin 2; Diabetes Mellitus, Type 2; Edema; Female; Genetic Predisposition to Dise | 2011 |
Fluid retention after initiation of thiazolidinedione therapy in diabetic patients with established chronic heart failure.
Topics: Adult; Aged; Ascites; Diabetes Complications; Diabetes Mellitus; Dilatation, Pathologic; Edema; Fema | 2003 |
Antiedematogenic activity of two thiazolidine derivatives: N-tryptophyl-5-(3,5-di-tert-butyl-4-hydroxybenzylidene) rhodanine (GS26) and N-tryptophyl-5-(3,5-di-tert-butyl-4-hydroxybenzylidene)-2,4-thiazolidinedione (GS28).
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Dose-Response Relationship, Drug; Edema; Female; M | 2003 |
Prevalence of edema in patients receiving combination therapy with insulin and thiazolidinedione.
Topics: Adult; Aged; Aged, 80 and over; Drug Therapy, Combination; Edema; Female; Humans; Insulin; Male; Mid | 2004 |
Continuation of thiazolidinedione therapy in patients without left ventricular dysfunction who developed edema and congestive-heart-failure symptoms.
Topics: Aged; Aged, 80 and over; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Edema; Female; | 2004 |
Plasma concentrations of vascular endothelial growth factor are associated with peripheral oedema in patients treated with thiazolidinedione.
Topics: Adult; Aged; Diabetes Mellitus, Type 2; Edema; Female; Humans; Male; Middle Aged; Thiazolidinediones | 2006 |
Management of thiazolidinedione-induced oedema: minimizing collateral damage.
Topics: Diabetes Mellitus; Edema; Humans; Hypoglycemic Agents; Thiazolidinediones | 2008 |
Synthesis and three-dimensional qualitative structure selectivity relationship of 3,5-disubstituted-2,4-thiazolidinedione derivatives as COX2 inhibitors.
Topics: Animals; Carrageenan; Catalytic Domain; Computer Simulation; Crystallography, X-Ray; Cyclooxygenase | 2007 |
Combination of insulin and thiazolidinedione therapy in massively obese patients with Type 2 diabetes.
Topics: Adult; Aged; Body Mass Index; Body Weight; Diabetes Complications; Diabetes Mellitus, Type 2; Drug T | 2002 |